文献速递先天性心脏病外科心外重症与机械循环支持

系统性心室辅助装置支持Fontan循环结局良好:基于美国胸外科医师学会Pedimacs与Intermacs数据库的分析

Systemic ventricular assist device support of the Fontan circulation yields promising outcomes: An analysis of The Society of Thoracic Surgeons Pedimacs and Intermacs Databases.
PubMed 文献 · J Thorac Cardiovasc Surg · 2021-11-27

该回顾性分析纳入2012年9月19日至2019年12月31日Pedimacs与Intermacs数据库中55例接受VAD植入的Fontan循环患者,中位植入年龄10.2岁,装置6个月生存率76%,6个月复合正面结局(存活带装置、移植或恢复)81%,结论认为VAD支持Fontan循环可取得良好结局。

要点

  • 55例Fontan循环患者接受VAD植入,中位年龄10.2岁,中位支持时间3.8个月。
  • 装置6个月Kaplan-Meier生存率76%,不同年代间无差异。
  • 6个月复合正面结局81%,58%的死亡发生在第1个月。

核心结论

  • 这是目前关于Fontan患者系统性VAD支持的最大规模分析,VAD支持Fontan循环正变得越来越频繁,该分析表明VAD在这一增长人群中的应用可取得良好结局。

研究设计与样本

  • 回顾性分析2012年9月19日至2019年12月31日美国胸外科医师学会Pedimacs与Intermacs数据库中接受VAD植入的Fontan循环患者,共识别55例。

主要发现

  • 中位植入年龄10.2岁(四分位距6.4-16.9岁),体重26.8 kg(原文此处写作四分位距17.7-53.8 years,按上下文应为kg)。
  • 2018-2019年植入VAD例数多于2012-2017年(28 vs 27;P=0.01)。
  • 后期年代VAD前肾小球滤过率更高(101.1±48.5 vs 71.2±34.9;P=0.02),Interagency Registry for Mechanically Assisted Circulatory Support分级无差异(P=0.69)。
  • 装置上Kaplan-Meier生存率6个月为76%,不同年代间无差异;竞争结局显示6个月正面结局(存活带VAD、移植或恢复)为81%,58%的死亡发生在第1个月。
  • 中位支持时间3.8个月(四分位距0.6-6.9个月);5例支持超过1年且无额外死亡,最长支持时间为4年7个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcomes of ventricular assist device (VAD) support in patients with Fontan circulatory failure (or failing Fontan physiology) are largely unknown. METHODS: We conducted a retrospective analysis of patients with a Fontan circulation who underwent VAD implant in the Society of Thoracic Surgeons Pedimacs and Intermacs Databases from September 19, 2012, to December 31, 2019. RESULTS: We identified 55 Fontan patients who had undergone VAD implant with a median age at implantation of 10.2 years (interquartile range, 6.4-16.9 years) and weight, 26.8 kg (interquartile range, 17.7-53.8 years). More VADs were implanted in 2018-2019 than in 2012-2017 (28 vs 27; P = .01). The later era had higher pre-VAD glomerular filtration rate (101.1 ± 48.5 vs 71.2 ± 34.9; P = .02); there was no difference in Interagency Registry for Mechanically Assisted Circulatory Support profile (P = .69). Kaplan-Meier survival on device was 76% at 6 months with no difference by era. Competing outcomes demonstrated a positive outcome of 81% (alive on VAD, transplanted, or recovered) at 6 months, with 58% of mortality occurring during month 1. Median length of support was 3.8 months (interquartile range, 0.6-6.9 months). Five patients were supported for >1 year with no added mortality; the longest support time was 4 years, 7 months. Adverse event rates included pump thrombosis incidence of 4% (3.3 out of 100 patient-months), stroke 5.5% (1.4 out of 100 patient-months), gastrointestinal bleeding of 7% (2.6 out of 100 patient-months), and nongastrointestinal bleeding of 9% (2.3 out of 100 patient-months). CONCLUSIONS: This is the largest reported analysis of systemic VAD support of Fontan patients. VAD support of the Fontan circulation is becoming more frequent. This analysis demonstrates that VAD use in this growing population can yield promising outcomes.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bedzra EKS, Adachi I, Peng DM, et al. Systemic ventricular assist device support of the Fontan circulation yields promising outcomes: An analysis of The Society of Thoracic Surgeons Pedimacs and Intermacs Databases. J Thorac Cardiovasc Surg. 2021. PMID: 35016782. doi:10.1016/j.jtcvs.2021.11.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。